C4 Therapeutics (CCCC) Stock Forecast, Price Target & Predictions
CCCC Stock Forecast
C4 Therapeutics stock forecast is as follows: an average price target of $11.33 (represents a 109.04% upside from CCCC’s last price of $5.42) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
CCCC Price Target
The average price target for C4 Therapeutics (CCCC) is $11.33 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $9.00. This represents a potential 109.04% upside from CCCC's last price of $5.42.
CCCC Analyst Ratings
According to 3 Wall Street analysts, C4 Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for CCCC stock is 0 'Strong Buy' (0.00%), 1 'Buy' (33.33%), 2 'Hold' (66.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
C4 Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 03, 2023 | - | Wells Fargo | $9.00 | $6.31 | 42.63% | 66.05% |
| Apr 28, 2022 | - | Credit Suisse | $10.00 | $8.85 | 12.99% | 84.50% |
| Apr 11, 2022 | Chi Fong | Bank of America Securities | $15.00 | $8.01 | 87.27% | 176.75% |
The latest C4 Therapeutics stock forecast, released on Jan 03, 2023 by Wells Fargo company, set a price target of $9.00, which represents a 42.63% increase from the stock price at the time of the forecast ($6.31), and a 66.05% increase from CCCC last price ($5.42).
C4 Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $5.42 | $5.42 | $5.42 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of C4 Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to C4 Therapeutics's last price of $5.42. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 13, 2023 | Piper Sandler | - | Buy | Upgrade |
| Feb 24, 2023 | Credit Suisse | Underperform | Neutral | Upgrade |
| Jan 03, 2023 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| Apr 28, 2022 | Credit Suisse | - | Underperform | Initialise |
C4 Therapeutics's last stock rating was published by Piper Sandler on Dec 13, 2023. The company Upgrade its CCCC rating from "null" to "Buy".
C4 Therapeutics Financial Forecast
C4 Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $2.66M | $3.76M | $2.85M | $6.75M | - | $7.65M | $20.08M | $8.50M | $9.78M | $7.43M | $8.26M | $8.45M |
| Avg Forecast | $8.84M | $5.00M | $4.00M | $5.00M | $7.62M | $5.83M | $4.78M | $11.99M | $3.20M | $5.28M | $6.41M | $5.46M | $9.87M | $8.45M | $7.64M | $7.81M | $7.41M | $7.61M | $6.29M | $3.87M | $8.00M | $6.07M |
| High Forecast | $8.84M | $5.00M | $4.00M | $5.00M | $7.62M | $8.24M | $4.78M | $11.99M | $7.17M | $5.28M | $6.41M | $5.46M | $9.87M | $8.45M | $7.64M | $11.50M | $10.91M | $11.21M | $9.27M | $5.69M | $11.79M | $8.94M |
| Low Forecast | $8.84M | $5.00M | $4.00M | $5.00M | $7.62M | $2.94M | $4.78M | $11.99M | $735.29K | $5.28M | $6.41M | $5.46M | $9.87M | $8.45M | $7.64M | $5.14M | $4.88M | $5.01M | $4.14M | $2.55M | $5.27M | $4.00M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.42% | 0.69% | 0.29% | 0.80% | - | 0.98% | 2.71% | 1.12% | 1.55% | 1.92% | 1.03% | 1.39% |
C4 Therapeutics's average Quarter revenue forecast for Sep 23 based on 8 analysts is $5.28M, with a low forecast of $5.28M, and a high forecast of $5.28M. CCCC's average Quarter revenue forecast represents a 98.06% increase compared to the company's last Quarter revenue of $2.66M (Jun 23).
C4 Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-27.81M | $-35.32M | $-34.17M | $-36.06M | $-30.99M | - | $-30.79M | $-14.80M | $-23.81M | $-21.66M | $-19.99M | $-20.50M | $-21.23M |
| Avg Forecast | $-8.84M | $-5.00M | $-4.00M | $-5.00M | $-7.62M | $-5.83M | $-4.78M | $-37.67M | $-3.20M | $-5.28M | $-6.41M | $-34.25M | $-9.87M | $-30.12M | $-7.64M | $-27.07M | $-19.52M | $-27.39M | $-24.91M | $-24.43M | $-8.00M | $-386.25M |
| High Forecast | $-8.84M | $-5.00M | $-4.00M | $-5.00M | $-7.62M | $-2.94M | $-4.78M | $-30.14M | $-735.29K | $-5.28M | $-6.41M | $-27.40M | $-9.87M | $-24.10M | $-7.64M | $-21.66M | $-15.61M | $-21.91M | $-19.93M | $-19.54M | $-5.27M | $-309.00M |
| Low Forecast | $-8.84M | $-5.00M | $-4.00M | $-5.00M | $-7.62M | $-8.24M | $-4.78M | $-45.21M | $-7.17M | $-5.28M | $-6.41M | $-41.10M | $-9.87M | $-36.15M | $-7.64M | $-32.49M | $-23.42M | $-32.86M | $-29.89M | $-29.31M | $-11.79M | $-463.50M |
| Surprise % | - | - | - | - | - | - | - | - | - | 5.27% | 5.51% | 1.00% | 3.65% | 1.03% | - | 1.14% | 0.76% | 0.87% | 0.87% | 0.82% | 2.56% | 0.05% |
undefined analysts predict CCCC's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than C4 Therapeutics's previous annual EBITDA (undefined) of $NaN.
C4 Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | $-27.04M | $-35.92M | $-33.94M | $-36.08M | $-31.43M | - | $-31.87M | $-16.20M | $-24.68M | $-22.58M | $-20.97M | $-21.80M | $-21.84M |
| Avg Forecast | $-22.94M | $-25.23M | $-27.29M | $-26.61M | $-25.26M | $-26.15M | $-25.07M | $-38.69M | $-47.27M | $-45.64M | $-47.09M | $-35.17M | $-51.18M | $-31.22M | $-47.36M | $-27.80M | $-20.65M | $-28.39M | $-25.97M | $-25.63M | $-27.14M | $-397.26M |
| High Forecast | $-22.94M | $-25.23M | $-27.29M | $-26.61M | $-25.26M | $-18.30M | $-25.07M | $-30.95M | $-31.04M | $-33.19M | $-47.09M | $-28.14M | $-51.18M | $-24.98M | $-47.36M | $-22.24M | $-16.52M | $-22.71M | $-20.77M | $-20.50M | $-15.09M | $-317.81M |
| Low Forecast | $-22.94M | $-25.23M | $-27.29M | $-26.61M | $-25.26M | $-30.07M | $-25.07M | $-46.43M | $-61.38M | $-57.40M | $-47.09M | $-42.21M | $-51.18M | $-37.47M | $-47.36M | $-33.36M | $-24.78M | $-34.06M | $-31.16M | $-30.76M | $-43.83M | $-476.71M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.59% | 0.76% | 0.96% | 0.70% | 1.01% | - | 1.15% | 0.78% | 0.87% | 0.87% | 0.82% | 0.80% | 0.05% |
C4 Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CCCC's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
C4 Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | $10.53M | $10.31M | $10.95M | $10.49M | $9.58M | - | $12.82M | $8.78M | $8.45M | $8.61M | $7.41M | $6.73M | $2.86M |
| Avg Forecast | $8.18M | $4.63M | $3.70M | $4.63M | $7.05M | $5.40M | $4.42M | $11.10M | $2.96M | $4.88M | $5.93M | $5.05M | $9.13M | $7.82M | $7.07M | $7.22M | $6.85M | $7.04M | $5.82M | $3.58M | $7.40M | $5.61M |
| High Forecast | $8.18M | $4.63M | $3.70M | $4.63M | $7.05M | $7.62M | $4.42M | $11.10M | $6.63M | $4.88M | $5.93M | $5.05M | $9.13M | $7.82M | $7.07M | $10.64M | $10.10M | $10.37M | $8.58M | $5.27M | $10.90M | $8.27M |
| Low Forecast | $8.18M | $4.63M | $3.70M | $4.63M | $7.05M | $2.72M | $4.42M | $11.10M | $680.20K | $4.88M | $5.93M | $5.05M | $9.13M | $7.82M | $7.07M | $4.76M | $4.51M | $4.63M | $3.83M | $2.35M | $4.87M | $3.70M |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.16% | 1.74% | 2.17% | 1.15% | 1.23% | - | 1.78% | 1.28% | 1.20% | 1.48% | 2.07% | 0.91% | 0.51% |
C4 Therapeutics's average Quarter SG&A projection for Dec 23 is $2.96M, based on 6 Wall Street analysts, with a range of $680.20K to $6.63M. The forecast indicates a -71.85% fall compared to CCCC last annual SG&A of $10.53M (Sep 23).
C4 Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 3 | 6 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 4 | 6 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.55 | $-0.73 | $-0.69 | $-0.74 | $-0.64 | - | $-0.65 | $-0.33 | $-0.51 | $-0.51 | $-0.49 | $-0.53 | $-0.66 |
| Avg Forecast | $-0.33 | $-0.37 | $-0.40 | $-0.39 | $-0.37 | $-0.38 | $-0.36 | $-0.36 | $-0.69 | $-0.66 | $-0.68 | $-0.75 | $-0.74 | $-0.71 | $-0.69 | $-0.62 | $-0.58 | $-0.57 | $-0.59 | $-0.63 | $-0.53 | $-0.63 |
| High Forecast | $-0.33 | $-0.37 | $-0.40 | $-0.39 | $-0.37 | $-0.27 | $-0.36 | $-0.36 | $-0.45 | $-0.48 | $-0.68 | $-0.75 | $-0.74 | $-0.71 | $-0.69 | $-0.34 | $-0.32 | $-0.32 | $-0.33 | $-0.35 | $-0.29 | $-0.35 |
| Low Forecast | $-0.33 | $-0.37 | $-0.40 | $-0.39 | $-0.37 | $-0.44 | $-0.36 | $-0.36 | $-0.89 | $-0.83 | $-0.68 | $-0.75 | $-0.74 | $-0.71 | $-0.69 | $-1.00 | $-0.93 | $-0.93 | $-0.95 | $-1.02 | $-0.86 | $-1.02 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.83% | 1.07% | 0.92% | 0.99% | 0.90% | - | 1.05% | 0.57% | 0.89% | 0.86% | 0.78% | 1.01% | 1.05% |
According to undefined Wall Street analysts, C4 Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CCCC previous annual EPS of $NaN (undefined).
C4 Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IPSC | Century Therapeutics | $1.46 | $20.00 | 1269.86% | Buy |
| STTK | Shattuck Labs | $3.50 | $12.00 | 242.86% | Buy |
| ARVN | Arvinas | $24.40 | $75.36 | 208.85% | Buy |
| RZLT | Rezolute | $4.35 | $12.50 | 187.36% | Buy |
| EWTX | Edgewise Therapeutics | $17.52 | $48.00 | 173.97% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| FHTX | Foghorn Therapeutics | $7.53 | $18.00 | 139.04% | Buy |
| CCCC | C4 Therapeutics | $5.40 | $11.33 | 109.81% | Hold |
| PRLD | Prelude Therapeutics | $4.85 | $8.75 | 80.41% | Sell |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| ELYM | Eliem Therapeutics | $7.39 | $13.00 | 75.91% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $41.84 | $51.20 | 22.37% | Buy |
| NRIX | Nurix Therapeutics | $23.33 | $27.57 | 18.17% | Buy |
| KYMR | Kymera Therapeutics | $45.40 | $51.10 | 12.56% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
CCCC Forecast FAQ
Is C4 Therapeutics a good buy?
No, according to 3 Wall Street analysts, C4 Therapeutics (CCCC) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 33.33% of CCCC's total ratings.
What is CCCC's price target?
C4 Therapeutics (CCCC) average price target is $11.33 with a range of $9 to $15, implying a 109.04% from its last price of $5.42. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will C4 Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CCCC stock, the company can go up by 109.04% (from the last price of $5.42 to the average price target of $11.33), up by 176.75% based on the highest stock price target, and up by 66.05% based on the lowest stock price target.
Can C4 Therapeutics stock reach $8?
CCCC's average twelve months analyst stock price target of $11.33 supports the claim that C4 Therapeutics can reach $8 in the near future.
What are C4 Therapeutics's analysts' financial forecasts?
C4 Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $30.23M (high $32.64M, low $27.34M), average EBITDA is $-55.911M (high $-45.484M, low $-65.847M), average net income is $-115M (high $-99.59M, low $-127M), average SG&A $27.97M (high $30.19M, low $25.29M), and average EPS is $-1.476 (high $-1.362, low $-1.533). CCCC's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $22.84M (high $22.84M, low $22.84M), average EBITDA is $-22.842M (high $-22.842M, low $-22.842M), average net income is $-102M (high $-102M, low $-102M), average SG&A $21.13M (high $21.13M, low $21.13M), and average EPS is $-1.483 (high $-1.483, low $-1.483).
Did the CCCC's actual financial results beat the analysts' financial forecasts?
Based on C4 Therapeutics's last annual report (Dec 2022), the company's revenue was $31.1M, which missed the average analysts forecast of $33.77M by -7.91%. Apple's EBITDA was $-126M, beating the average prediction of $-74.707M by 68.60%. The company's net income was $-126M, missing the average estimation of $-158M by -19.71%. Apple's SG&A was $42.79M, beating the average forecast of $31.24M by 36.99%. Lastly, the company's EPS was $-2.59, missing the average prediction of $-2.764 by -6.30%. In terms of the last quarterly report (Jun 2023), C4 Therapeutics's revenue was $2.66M, missing the average analysts' forecast of $6.41M by -58.46%. The company's EBITDA was $-35.322M, beating the average prediction of $-6.412M by 450.84%. C4 Therapeutics's net income was $-35.922M, missing the average estimation of $-47.087M by -23.71%. The company's SG&A was $10.31M, beating the average forecast of $5.93M by 73.74%. Lastly, the company's EPS was $-0.73, beating the average prediction of $-0.684 by 6.68%